MetLife, 5.875% Senior Notes due 11/21/2033 (MLG)

Financing Cash Flow

$5.27B

TTM · Period ending: · USD

MLG logo

MLG Financing Cash Flow

Latest reported$5.27B
MLG TTM Cash from Financing (-$2.01B → $5.27B)
High-resolution chart · PNG

MLG financing cash flow history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

MetLife, 5.875% Senior Notes due 11/21/2033 Financing Cash Flow — Trailing twelve months (TTM) (USD)
Period endingFinancing Cash Flow (USD)
5,269,000,000
3,502,000,000
163,000,000
642,000,000
4,000,000
-2,650,000,000
-3,131,000,000
-2,788,000,000
-2,490,000,000
-906,000,000
-2,940,000,000
-7,232,000,000
-4,641,000,000
-14,108,000,000
-9,948,000,000
-6,815,000,000
-9,666,000,000
1,054,000,000
-1,375,000,000
-7,033,000,000
-3,040,000,000
-3,992,000,000
10,729,000,000
16,713,000,000
16,155,000,000
16,409,000,000
4,568,000,000
2,245,000,000
-1,163,000,000
-703,000,000
-2,801,000,000
-2,064,000,000
-100,000,000
-2,187,000,000
-906,000,000
-10,089,000,000
-10,360,000,000
-6,291,000,000
-3,499,000,000
9,836,000,000
8,936,000,000
1,273,000,000
-1,295,000,000
-2,573,000,000
126,000,000
7,638,000,000
2,256,000,000
654,000,000
-3,551,000,000
-13,890,000,000
-8,907,000,000
-12,801,000,000
-12,046,000,000
1,119,000,000
35,000,000
3,452,000,000
9,087,000,000
7,360,000,000
9,382,000,000
5,934,000,000
13,106,000,000
11,798,000,000
13,381,000,000
18,652,000,000
3,760,000,000
1,910,000,000
-4,103,000,000
-7,146,000,000
-2,309,000,000
-634,000,000
6,188,000,000
-4,046,000,000
-5,341,000,000
-2,228,000,000
-2,868,000,000
8,758,000,000
10,062,000,000
5,500,000,000
15,362,000,000
11,347,000,000
16,775,000,000
23,209,000,000
14,513,000,000
21,469,000,000
17,265,000,000
11,799,000,000
7,881,000,000
8,020,000,000
7,214,000,000
9,733,000,000
11,657,000,000
13,267,000,000
13,383,000,000
9,215,000,000
6,849,000,000
6,066,000,000
3,297,000,000
2,830,000,000
2,903,000,000
140,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.